Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Statin Clear all
Completed Phase 3 Interventional Results available

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

NCT04929249
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

NCT01859455
View directory record Official record
Conditions
Hypercholesterolemia, LDL Cholesterol
Interventions
LGT209 50 mg, LGT209 300 mg, Placebo, Statins (atorvastatin or simvastatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy

NCT04164888
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CIVI 007
Drug
Lead sponsor
Civi Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Jacksonville, Florida • Port Orange, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 3 Interventional

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia

NCT00766688
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AVE5530, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

NCT02926027
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Vascepa, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

NCT01702246
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Simvastatin
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

Statins for the Early Treatment of Sepsis

NCT00528580
View directory record Official record
Conditions
Sepsis
Interventions
Simvastatin, Identical-appearing placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Not applicable Interventional Results available

Social Forces to Improve Statin Adherence (Study B)

NCT02148523
View directory record Official record
Conditions
Medication Adherence, High Blood Pressure, Diabetes
Interventions
Comparison to peers, Adherence feedback, Electronic pill bottle
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 18, 2026, 3:23 AM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 18, 2026, 3:23 AM EDT
Completed No phase listed Observational

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

NCT01592084
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 18, 2026, 3:23 AM EDT
Not yet recruiting Phase 2 Interventional

Vascular Intervention Strategies Trial for Alzheimer's

NCT07447206
View directory record Official record
Conditions
Hypertension, Hypercholesterolemia, Dementia Risk Factors
Interventions
Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative
Drug
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Recruiting Phase 2 Interventional

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164
View directory record Official record
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 18, 2026, 3:23 AM EDT
Not listed Phase 2 Interventional

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

NCT02532218
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ARI-3037MO
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A BCT Intervention for Physical Activity Among Individuals on Statins

NCT05273723
View directory record Official record
Conditions
Insufficient Physical Activity
Interventions
5 Behavioral Change Techniques
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 4 Interventional

The Effect of Statin Use on Vascular Function in Hypertensive Subjects

NCT00181181
View directory record Official record
Conditions
Hypertension
Interventions
atorvastatin, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
20 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2010 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

NCT01972178
View directory record Official record
Conditions
Dyslipidemia
Interventions
PRC-4016, Placebo, Statins
Drug
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 18, 2026, 3:23 AM EDT
Completed No phase listed Observational

Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease

NCT00293748
View directory record Official record
Conditions
Vascular Disease, Vascular Disease Risk
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Lipitor as a Treatment for Alzheimer's Disease

NCT00024531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Institute for the Study of Aging (ISOA)
Other
Eligibility
50 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2006 · Synced Oct 18, 2026, 3:23 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Butyrate Tablet BKR-017

NCT06556745
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
BKR-017
Drug
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Statin Therapy in Young Adult Survivors of Childhood Cancer

NCT01733953
View directory record Official record
Conditions
Cardiovascular Disease, Childhood ALL, Childhood NHL
Interventions
Atorvastatin, Sugar Pill (Placebo)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 18, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of Long Term Safety Evaluation of Alirocumab

NCT01954394
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
44
States / cities
Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 18, 2026, 3:23 AM EDT
Terminated Phase 4 Interventional Results available

Risk Factor Control Before Orthopedic Surgery

NCT01837069
View directory record Official record
Conditions
Osteoarthritis, Cardiovascular Disease
Interventions
Metoprolol, Lisinopril, Atorvastatin, Lifestyle counseling
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 18, 2026, 3:23 AM EDT